Adaptimmune Therapeutics (ADAP) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ADAP Stock Forecast


Adaptimmune Therapeutics stock forecast is as follows: an average price target of $2.83 (represents a 241.99% upside from ADAP’s last price of $0.83) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ADAP Price Target


The average price target for Adaptimmune Therapeutics (ADAP) is $2.83 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $1.00. This represents a potential 241.99% upside from ADAP's last price of $0.83.

ADAP Analyst Ratings


Buy

According to 5 Wall Street analysts, Adaptimmune Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ADAP stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Adaptimmune Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 30, 2024Arthur HeH.C. Wainwright$4.00$1.37191.97%383.38%
May 30, 2024George FarmerScotiabank$3.15$1.01211.88%280.66%
May 17, 2024Graig SuvannavejhMizuho Securities$3.00$1.20150.00%262.54%
May 16, 2024Peter LawsonBarclays$1.00$1.20-16.67%20.85%
Nov 14, 2022-Wells Fargo$3.00$2.5119.52%262.54%
Row per page
Go to

The latest Adaptimmune Therapeutics stock forecast, released on Jul 30, 2024 by Arthur He from H.C. Wainwright, set a price target of $4.00, which represents a 191.97% increase from the stock price at the time of the forecast ($1.37), and a 383.38% increase from ADAP last price ($0.83).

Adaptimmune Therapeutics Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$2.79
Last Closing Price$0.83$0.83$0.83
Upside/Downside-100.00%-100.00%237.16%

In the current month, the average price target of Adaptimmune Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptimmune Therapeutics's last price of $0.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 05, 2024ScotiabankSector OutperformSector OutperformHold
Aug 05, 2024H.C. WainwrightUnderperformUnderperformHold
Jul 30, 2024H.C. Wainwright-BuyInitialise
May 31, 2024Wells FargoEqual-WeightEqual-WeightHold
May 30, 2024Scotiabank-OutperformInitialise
May 16, 2024BarclaysUnderweightUnderweightHold
Jan 03, 2023Guggenheim-BuyUpgrade
Nov 09, 2022Bank of America Securities-BuyUpgrade
Nov 09, 2022Mizuho Securities-BuyUpgrade
Row per page
Go to

Adaptimmune Therapeutics's last stock rating was published by Scotiabank on Aug 05, 2024. The company gave ADAP a "Sector Outperform" rating, the same as its previous rate.

Adaptimmune Therapeutics Financial Forecast


Adaptimmune Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$231.00K$7.32M$5.13M$47.60M$11.03M$7.01M$5.54M$3.58M$1.42M$1.20M$3.10M$434.00K$1.50M$1.19M$502.00K$761.00K$728.00K$237.00K
Avg Forecast$629.08M$536.64M$457.79M$390.52M$11.33M$9.23M$7.63M$6.23M$11.08M$18.57M$40.47M$9.88M$25.96M$7.97M$6.13M$5.15M$3.83M$6.93M$6.57M$3.50M$4.50M$1.53M$1.40M$1.83M$1.80M$1.02M$7.94M$23.29M$1.30M$1.48M
High Forecast$629.08M$536.64M$457.79M$390.52M$11.33M$9.23M$7.63M$6.23M$11.08M$22.90M$40.47M$9.88M$25.96M$7.97M$6.13M$5.15M$3.83M$6.93M$6.57M$3.50M$4.50M$1.53M$1.40M$1.83M$1.80M$1.02M$7.94M$23.29M$1.30M$1.48M
Low Forecast$629.08M$536.64M$457.79M$390.52M$11.33M$9.23M$7.63M$6.23M$11.08M$14.23M$40.47M$9.88M$25.96M$7.97M$6.13M$5.15M$3.83M$6.93M$6.57M$3.50M$4.50M$1.53M$1.40M$1.83M$1.80M$1.02M$7.94M$23.29M$1.30M$1.48M
# Analysts4444333345413111111111111016811711
Surprise %------------0.01%0.92%0.84%9.24%2.88%1.01%0.84%1.02%0.31%0.78%2.21%0.24%0.83%1.17%0.06%0.03%0.56%0.16%

Adaptimmune Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.88M, with a low forecast of $9.88M, and a high forecast of $9.88M. ADAP's average Quarter revenue forecast represents a 4177.06% increase compared to the company's last Quarter revenue of $231.00K (Dec 23).

Adaptimmune Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333345413111111111111016811711
EBITDA------------$-47.26M$-46.29M$-64.83M$3.50M$-27.24M$-41.50M$-42.20M$-48.39M$-36.41M$-40.74M$-37.55M$-36.03M$-34.84M$-33.59M$-27.70M$-26.21M$-27.18M$-37.27M
Avg Forecast$-629.08M$-536.64M$-457.79M$-390.52M$-11.33M$-9.23M$-7.63M$-6.23M$-11.08M$-18.57M$-40.47M$-26.54M$-25.96M$-7.97M$-6.13M$-28.38M$-31.16M$-6.93M$-6.57M$-30.35M$-4.50M$-1.53M$-1.40M$-37.47M$-1.80M$-1.02M$-7.94M$-25.36M$-1.30M$-1.48M
High Forecast$-629.08M$-536.64M$-457.79M$-390.52M$-11.33M$-9.23M$-7.63M$-6.23M$-11.08M$-14.23M$-40.47M$-21.23M$-25.96M$-7.97M$-6.13M$-22.70M$-24.92M$-6.93M$-6.57M$-24.28M$-4.50M$-1.53M$-1.40M$-29.98M$-1.80M$-1.02M$-7.94M$-20.29M$-1.30M$-1.48M
Low Forecast$-629.08M$-536.64M$-457.79M$-390.52M$-11.33M$-9.23M$-7.63M$-6.23M$-11.08M$-22.90M$-40.47M$-31.84M$-25.96M$-7.97M$-6.13M$-34.06M$-37.39M$-6.93M$-6.57M$-36.42M$-4.50M$-1.53M$-1.40M$-44.96M$-1.80M$-1.02M$-7.94M$-30.43M$-1.30M$-1.48M
Surprise %------------1.82%5.81%10.58%-0.12%0.87%5.99%6.42%1.59%8.09%26.57%26.82%0.96%19.35%33.04%3.49%1.03%20.91%25.18%

1 analysts predict ADAP's average Quarter EBITDA for Jun 23 to be $-6.13M, with a high of $-6.13M and a low of $-6.13M. This is -275.05% lower than Adaptimmune Therapeutics's previous annual EBITDA (Mar 23) of $3.50M.

Adaptimmune Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333345413111111111111016811711
Net Income------------$-47.92M$-45.60M$-21.39M$1.04M$-29.25M$-41.42M$-44.52M$-50.27M$-38.86M$-42.40M$-39.07M$-37.76M$-36.61M$-35.43M$-29.88M$-28.17M$-29.36M$-39.30M
Avg Forecast$-42.77M$-44.10M$-47.63M$-48.96M$-31.96M$-32.76M$-32.42M$-33.22M$-7.36M$-3.04M$-11.39M$-27.96M$-42.88M$-50.41M$-37.72M$-29.91M$-32.74M$-64.97M$-75.36M$-31.99M$31.70M$-68.55M$-9.74M$-39.27M$-60.63M$-65.83M$-61.50M$-29.29M$-88.35M$-79.26M
High Forecast$-42.77M$-44.10M$-47.63M$-48.96M$-31.96M$-32.76M$-32.42M$-33.22M$-7.36M$-1.79M$-11.39M$-22.37M$-25.01M$-50.41M$-37.72M$-23.93M$-26.20M$-64.97M$-75.36M$-25.59M$31.70M$-68.55M$-9.74M$-31.42M$-60.63M$-65.83M$-61.50M$-23.43M$-88.35M$-79.26M
Low Forecast$-42.77M$-44.10M$-47.63M$-48.96M$-31.96M$-32.76M$-32.42M$-33.22M$-7.36M$-4.30M$-11.39M$-33.56M$-57.17M$-50.41M$-37.72M$-35.89M$-39.29M$-64.97M$-75.36M$-38.38M$31.70M$-68.55M$-9.74M$-47.13M$-60.63M$-65.83M$-61.50M$-35.15M$-88.35M$-79.26M
Surprise %------------1.12%0.90%0.57%-0.03%0.89%0.64%0.59%1.57%-1.23%0.62%4.01%0.96%0.60%0.54%0.49%0.96%0.33%0.50%

Adaptimmune Therapeutics's average Quarter net income forecast for Jun 23 is $-37.72M, with a range of $-37.72M to $-37.72M. ADAP's average Quarter net income forecast represents a -3740.85% decrease compared to the company's last Quarter net income of $1.04M (Mar 23).

Adaptimmune Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333345413111111111111016811711
SG&A------------$16.88M$16.16M$20.07M$20.40M$15.22M$16.82M$16.89M$16.80M$15.48M$15.17M$14.99M$13.82M$13.24M$13.00M$10.29M$9.26M$10.73M$10.74M
Avg Forecast$7.88B$6.72B$5.74B$4.89B$142.02M$115.70M$95.65M$78.11M$138.84M$232.67M$507.13M$9.35M$325.30M$99.89M$76.80M$64.53M$48.04M$86.82M$82.35M$43.86M$56.39M$19.21M$17.54M$22.97M$22.56M$12.74M$99.53M$9.63M$16.29M$18.55M
High Forecast$7.88B$6.72B$5.74B$4.89B$142.02M$115.70M$95.65M$78.11M$138.84M$287.01M$507.13M$11.22M$325.30M$99.89M$76.80M$64.53M$48.04M$86.82M$82.35M$43.86M$56.39M$19.21M$17.54M$22.97M$22.56M$12.74M$99.53M$11.56M$16.29M$18.55M
Low Forecast$7.88B$6.72B$5.74B$4.89B$142.02M$115.70M$95.65M$78.11M$138.84M$178.33M$507.13M$7.48M$325.30M$99.89M$76.80M$64.53M$48.04M$86.82M$82.35M$43.86M$56.39M$19.21M$17.54M$22.97M$22.56M$12.74M$99.53M$7.71M$16.29M$18.55M
Surprise %------------0.05%0.16%0.26%0.32%0.32%0.19%0.21%0.38%0.27%0.79%0.85%0.60%0.59%1.02%0.10%0.96%0.66%0.58%

Adaptimmune Therapeutics's average Quarter SG&A projection for Mar 24 is $9.35M, based on 1 Wall Street analysts, with a range of $7.48M to $11.22M. The forecast indicates a -44.61% fall compared to ADAP last annual SG&A of $16.88M (Dec 23).

Adaptimmune Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333345413111111111111016811711
EPS-------------$-0.34$-0.12$0.01$-0.18$-0.25$-0.28$-0.32$-0.25$-0.27$-0.25$-0.24$-0.24$-0.23$-0.22$-0.23$-0.28$-0.37
Avg Forecast$-0.16$-0.17$-0.18$-0.19$-0.12$-0.13$-0.12$-0.13$-0.03$-0.01$-0.04$-0.15$-0.17$-0.19$-0.15$-0.19$-0.24$-0.25$-0.29$-0.25$0.12$-0.26$-0.04$-0.04$-0.23$-0.25$-0.24$-0.25$-0.34$-0.30
High Forecast$-0.16$-0.17$-0.18$-0.19$-0.12$-0.13$-0.12$-0.13$-0.03$-0.01$-0.04$-0.15$-0.10$-0.19$-0.15$-0.19$-0.24$-0.25$-0.29$-0.25$0.12$-0.26$-0.04$-0.04$-0.23$-0.25$-0.24$-0.25$-0.34$-0.30
Low Forecast$-0.16$-0.17$-0.18$-0.19$-0.12$-0.13$-0.12$-0.13$-0.03$-0.02$-0.04$-0.15$-0.22$-0.19$-0.15$-0.19$-0.24$-0.25$-0.29$-0.25$0.12$-0.26$-0.04$-0.04$-0.23$-0.25$-0.24$-0.25$-0.34$-0.30
Surprise %-------------1.75%0.83%-0.03%0.73%1.00%0.97%1.26%-2.05%1.02%6.67%6.48%1.03%0.91%0.93%0.91%0.82%1.21%

According to 1 Wall Street analysts, Adaptimmune Therapeutics's projected average Quarter EPS for Jun 23 is $-0.15, with a low estimate of $-0.15 and a high estimate of $-0.15. This represents a -2403.97% decrease compared to ADAP previous annual EPS of $0.01 (Mar 23).

Adaptimmune Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ACETAdicet Bio$1.26$32.502479.37%Buy
SGMOSangamo Therapeutics$1.74$12.00589.66%Buy
NKTXNkarta$3.23$21.60568.73%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
ADAPAdaptimmune Therapeutics$0.83$2.83240.96%Buy
FIXXQ32 Bio$0.93$2.70190.32%Buy
PDSBPDS Bio$3.23$9.00178.64%Buy
PLRXPliant Therapeutics$14.49$39.71174.05%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
AFMDAffimed$3.27$7.50129.36%Buy
MREOMereo BioPharma Group$4.01$6.7568.33%Buy
LPTXLeap Therapeutics$3.67$5.5049.86%Buy
AGIOAgios Pharmaceuticals$44.83$48.718.65%Buy
CRVSCorvus Pharmaceuticals$9.02$9.505.32%Buy

ADAP Forecast FAQ


Yes, according to 5 Wall Street analysts, Adaptimmune Therapeutics (ADAP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ADAP's total ratings.

Adaptimmune Therapeutics (ADAP) average price target is $2.83 with a range of $1 to $4, implying a 241.99% from its last price of $0.828. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ADAP stock, the company can go up by 241.99% (from the last price of $0.828 to the average price target of $2.83), up by 383.38% based on the highest stock price target, and up by 20.85% based on the lowest stock price target.

ADAP's average twelve months analyst stock price target of $2.83 supports the claim that Adaptimmune Therapeutics can reach $1 in the near future.

Adaptimmune Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.43M (high $34.43M, low $34.43M), average EBITDA is $-34.433M (high $-34.433M, low $-34.433M), average net income is $-130M (high $-130M, low $-130M), average SG&A $431.48M (high $431.48M, low $431.48M), and average EPS is $-0.502 (high $-0.502, low $-0.502). ADAP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.01B (high $2.01B, low $2.01B), average EBITDA is $-2.014B (high $-2.014B, low $-2.014B), average net income is $-183M (high $-183M, low $-183M), average SG&A $25.24B (high $25.24B, low $25.24B), and average EPS is $-0.706 (high $-0.706, low $-0.706).

Based on Adaptimmune Therapeutics's last annual report (Dec 2023), the company's revenue was $60.28M, beating the average analysts forecast of $45.21M by 33.34%. Apple's EBITDA was $-115M, beating the average prediction of $-68.44M by 68.33%. The company's net income was $-114M, missing the average estimation of $-161M by -29.24%. Apple's SG&A was $73.51M, missing the average forecast of $566.52M by -87.02%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.69 by -99.99%. In terms of the last quarterly report (Dec 2023), Adaptimmune Therapeutics's revenue was $231K, missing the average analysts' forecast of $25.96M by -99.11%. The company's EBITDA was $-47.261M, beating the average prediction of $-25.96M by 82.05%. Adaptimmune Therapeutics's net income was $-47.917M, beating the average estimation of $-42.878M by 11.75%. The company's SG&A was $16.88M, missing the average forecast of $325.3M by -94.81%. Lastly, the company's EPS was $0, missing the average prediction of $-0.165 by -100.00%